T7650
3,3′,5-Triiodothyroacetic acid
≥90%
Synonym(s):
4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylacetic acid
Sign Into View Organizational & Contract Pricing
All Photos(4)
About This Item
Recommended Products
Quality Level
Assay
≥90%
form
powder
storage temp.
−20°C
SMILES string
OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1
InChI
1S/C14H9I3O4/c15-9-6-8(1-2-12(9)18)21-14-10(16)3-7(4-11(14)17)5-13(19)20/h1-4,6,18H,5H2,(H,19,20)
InChI key
UOWZUVNAGUAEQC-UHFFFAOYSA-N
Gene Information
human ... THRA(7067) , THRB(7068)
rat ... Thra(81812) , Thrb(24831)
Application
- Thyroid hormone research: A study explored the impact of 3,3′,5-Triiodothyroacetic acid on peripheral and neurodevelopmental findings in patients with MCT8 deficiency, highlighting its potential in therapeutic interventions for thyroid-related developmental disorders (Unsal and Hayran, 2024).
- Neurological disorder management: Research demonstrated the use of 3,3′,5-Triiodothyroacetic acid in addressing impaired T3 uptake and action in cerebral organoids modeling Allan-Herndon-Dudley syndrome, providing insights into its application in managing brain-specific thyroid hormone transport abnormalities (Salas-Lucia et al., 2024).
- Pharmaceutical development for antiviral therapies: Tiratricol, a derivative of 3,3′,5-Triiodothyroacetic acid, was identified as an inhibitor of yellow fever virus replication by targeting the viral RNA-dependent RNA polymerase, showcasing its potential in antiviral drug development (Ren et al., 2023).
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
Storage Class Code
13 - Non Combustible Solids
WGK
WGK 3
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Thyroid : official journal of the American Thyroid Association, 22(10), 1069-1075 (2012-09-06)
The effectiveness of short-term 3,5,3'-triiodothyroacetic acid (TRIAC) therapy for the treatment of hyperthyroidism caused by thyroid hormone resistance (RTH) has been documented. Here, we report a 3-year course of TRIAC therapy in an RTH boy, with a quantitative evaluation of
Bioorganic & medicinal chemistry, 15(13), 4609-4617 (2007-05-01)
2D QSAR studies were carried out for a series of 55 ligands for the Thyroid receptors, TRalpha and TRbeta. Significant cross-validated correlation coefficients (q(2)=0.781 (TRalpha) and 0.693 (TRbeta)) were obtained. The models' predictive abilities were proved more valuable than the
Journal of pain and symptom management, 43(4), 771-782 (2012-01-31)
Little is known about the treatment and correlates of dyspnea in idiopathic pulmonary fibrosis (IPF). The objective of this systematic review was to summarize the literature regarding the treatment and correlates of dyspnea in IPF. MEDLINE, EMBASE, and all Evidence-Based
Thyroid : official journal of the American Thyroid Association, 18(6), 655-657 (2008-06-27)
Mesotherapy consists of cutaneous injections of a mixture of compounds and has recently been used for cosmetic purposes to reduce local fat and cellulite. To date, several reports have described only local adverse events related to this therapy. We describe
Chembiochem : a European journal of chemical biology, 10(2), 361-365 (2008-12-24)
3-Iodothyronamine (T(1)AM) and 3,3',5-triiodothyroacetic acid (Triac) are bioactive metabolites of the hormone thyroxine (T(4)). In the present study, the ability of T(1)AM and 3,3',5-triiodothyronamine (T(3)AM) to be metabolized to 3-iodothyroacetic acid (TA(1)) and Triac, respectively, was investigated. Both T(1)AM and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service